VaporTheGamer plays Skeleton Tricky Phase 5 & Minecraft Steve in FNF.

VaporTheGamer plays FNF vs Neo Tabi & Tricky secret phase 4.5.

A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...

A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...

The U.S. Space Force has awarded SpaceX nine task orders worth $739 million combined to provide Lane 1 launch services under the National Security Space Launch, or NSSL, program’s third phase. The ...

Blue Origin’s New Glenn rocket at liftoff during the NG-2 mission on Nov. 13. Credit: Blue Origin The U.S. Space Force is now taking proposals from new launch providers with rockets ready to fly by ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Telitacicept shows efficacy and tolerability over 39 weeks in part A of a phase 3 study in patients with IgA nephropathy. Telitacicept reduces proteinuria over 39 weeks compared with placebo with ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...

Orforglipron, a once-daily oral GLP-1, met all primary and key secondary endpoints in ATTAIN-2, a phase 3, 72-week randomized, placebo-controlled trial, prompting Eli Lilly and Company to prepare ...